Aclaris Therapeutics ACRS Single Reportable — Licensing Expenses

Similar metrics at other companies

IOVASingle Reportable — Royalty Expense

$2.65M+99.8%

AMGNReportable Segment — Royalty Expense

$564M+28.2%

IOVASingle Reportable — Research And Development Expense

$57.37M-13.1%

PTGXSingle Reportable — Cost Of Revenue Discovery Expenses Excluding Employee Expense Benefit And Allocation Share Based Compensation Expenses

$8.51M+127%

LQD

LQDASingle Reportable — Program Expenses

$21.66M+64.4%

QURESingle Reportable — Laboratory And Development Expense

$14.76M-7.6%

Questions, answered.

What is Aclaris Therapeutics's single reportable — licensing expenses?

Aclaris Therapeutics (ACRS) reported single reportable — licensing expenses of $1.39M in Q1 2026.

How has Aclaris Therapeutics's single reportable — licensing expenses changed year-over-year?

Aclaris Therapeutics's single reportable — licensing expenses increased by 37.9% year-over-year, from $1.01M to $1.39M.

What does single reportable — licensing expenses mean?

Captures the costs associated with acquiring or maintaining licenses for intellectual property, technologies, or drug candidates from third parties. These expenses are vital for companies that rely on external innovation to supplement their internal research pipeline. It reflects the strategic cost of accessing external scientific assets.